RxDoctor Payments Data

Maria Goleba, MD

Internal Medicine · Davison, MINPI 1306834429

Payments from drug & device makers

$6,721in general payments, 2019–2025

Across 357 payments — averaging $18.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • Novo Nordisk$519
  • Amgen$396
  • Pfizer$372
  • Boehringer Ingelheim$340
  • plus $2K from 35 others

What the payments were for

  • Speaking & faculty fees$2504%
  • Travel & lodging$6149%
  • Food & beverage$5,82987%
  • Education$280%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,721 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$67,540
Medicare patients
344
Services billed
807

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide275$324,758
EliquisApixaban215$241,703
TrulicityDulaglutide131$132,646
JanuviaSitagliptin Phosphate75$105,371
Trelegy ElliptaFluticasone/Umeclidin/Vilanter117$87,958
JardianceEmpagliflozin55$56,775
XareltoRivaroxaban53$52,921
RybelsusSemaglutide19$33,482
Lantus SolostarInsulin Glargine,hum.Rec.Anlog196$31,827
TradjentaLinagliptin26$24,531
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate61$20,229
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog27$18,968
Combivent RespimatIpratropium/Albuterol Sulfate28$18,519
Atorvastatin Calcium1,127$15,229
MounjaroTirzepatide12$15,146

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$519$358,240294 claims
PfizerEliquis$372$241,703215 claims
Lilly USA, LLCTrulicity, Mounjaro$173$147,792143 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$125$110,211156 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat, Spiriva Respimat$340$106,597123 claims
Johnson & JohnsonXarelto$47$52,92153 claims
AstraZenecaBrilinta, Symbicort$1,031$15,57432 claims
NovartisEntresto$188$11,86414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Davison

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →